LOS ANGELES, United States: QY Research has recently published a report, titled Global CRISPR And CRISPR-Associated Genes Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global CRISPR And CRISPR-Associated Genes market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.
Key Companies/Manufacturers operating in the global CRISPR And CRISPR-Associated Genes market include: Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies CRISPR And CRISPR-Associated Genes
Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :
https://www.qyresearch.com/sample-form/form/1941094/global-crispr-and-crispr-associated-genes-market
Segmental Analysis
Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global CRISPR And CRISPR-Associated Genes market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.
Global CRISPR And CRISPR-Associated Genes Market Segment By Type:
CRISPR is a type of gene-editing technology that lets scientists more rapidly and accurately cut and paste genes into DNA. Market Analysis and Insights: Global CRISPR And CRISPR-Associated Genes Market The global CRISPR And CRISPR-Associated Genes market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global CRISPR And CRISPR-Associated Genes Scope and Market Size CRISPR And CRISPR-Associated Genes market is segmented 7, and 4. Players, stakeholders, and other participants in the global CRISPR And CRISPR-Associated Genes market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast 7 and 4 in terms of revenue and forecast for the period 2015-2026. The following players are covered in this report:Thermo Fisher ScientificEditas MedicineCaribou BiosciencesCRISPR therapeuticsIntellia therapeutics, Inc.CellectisHorizon Discovery PlcSigma AldrichPrecision BiosciencesGenscriptSangamo Biosciences Inc.Lonza Group LimitedIntegrated DNA TechnologiesNew England BiolabsOrigene Technologies CRISPR And CRISPR-Associated Genes
Global CRISPR And CRISPR-Associated Genes Market Segment By Application:
Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes
Competitive Landscape
Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global CRISPR And CRISPR-Associated Genes market.
Key companies operating in the global CRISPR And CRISPR-Associated Genes market include Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies CRISPR And CRISPR-Associated Genes
Key questions answered in the report:
For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1941094/global-crispr-and-crispr-associated-genes-market
TOC
1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by CRISPR And CRISPR-Associated Genes Revenue1.4 Market 71.4.1 Global CRISPR And CRISPR-Associated Genes Market Size Growth Rate 7: 2020 VS 20261.4.2 Genome Editing1.4.3 Genetic Engineering1.4.4 GRNA Database/Gene Librar1.4.5 CRISPR Plasmid1.4.6 Human Stem Cells1.4.7 Genetically Modified Organisms/Crops1.4.8 Cell Line Engineering1.5 Market by Application1.5.1 Global CRISPR And CRISPR-Associated Genes Market Share 4: 2020 VS 20261.5.2 Biotechnology Companies1.5.3 Pharmaceutical Companies1.5.4 Academic Institutes1.5.5 Research and Development Institutes1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global CRISPR And CRISPR-Associated Genes Market Perspective (2015-2026)2.2 Global CRISPR And CRISPR-Associated Genes Growth Trends by Regions2.2.1 CRISPR And CRISPR-Associated Genes Market Size by Regions: 2015 VS 2020 VS 20262.2.2 CRISPR And CRISPR-Associated Genes Historic Market Share by Regions (2015-2020)2.2.3 CRISPR And CRISPR-Associated Genes Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 CRISPR And CRISPR-Associated Genes Market Growth Strategy2.3.6 Primary Interviews with Key CRISPR And CRISPR-Associated Genes Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top CRISPR And CRISPR-Associated Genes Players by Market Size3.1.1 Global Top CRISPR And CRISPR-Associated Genes Players by Revenue (2015-2020)3.1.2 Global CRISPR And CRISPR-Associated Genes Revenue Market Share by Players (2015-2020)3.1.3 Global CRISPR And CRISPR-Associated Genes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global CRISPR And CRISPR-Associated Genes Market Concentration Ratio3.2.1 Global CRISPR And CRISPR-Associated Genes Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by CRISPR And CRISPR-Associated Genes Revenue in 20193.3 CRISPR And CRISPR-Associated Genes Key Players Head office and Area Served3.4 Key Players CRISPR And CRISPR-Associated Genes Product Solution and Service3.5 Date of Enter into CRISPR And CRISPR-Associated Genes Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size 7 (2015-2026)4.1 Global CRISPR And CRISPR-Associated Genes Historic Market Size 7 (2015-2020)4.2 Global CRISPR And CRISPR-Associated Genes Forecasted Market Size 7 (2021-2026) 5 Market Size 4 (2015-2026)5.1 Global CRISPR And CRISPR-Associated Genes Market Size 4 (2015-2020)5.2 Global CRISPR And CRISPR-Associated Genes Forecasted Market Size 4 (2021-2026) 6 North America6.1 North America CRISPR And CRISPR-Associated Genes Market Size (2015-2020)6.2 CRISPR And CRISPR-Associated Genes Key Players in North America (2019-2020)6.3 North America CRISPR And CRISPR-Associated Genes Market Size 7 (2015-2020)6.4 North America CRISPR And CRISPR-Associated Genes Market Size 4 (2015-2020) 7 Europe7.1 Europe CRISPR And CRISPR-Associated Genes Market Size (2015-2020)7.2 CRISPR And CRISPR-Associated Genes Key Players in Europe (2019-2020)7.3 Europe CRISPR And CRISPR-Associated Genes Market Size 7 (2015-2020)7.4 Europe CRISPR And CRISPR-Associated Genes Market Size 4 (2015-2020) 8 China8.1 China CRISPR And CRISPR-Associated Genes Market Size (2015-2020)8.2 CRISPR And CRISPR-Associated Genes Key Players in China (2019-2020)8.3 China CRISPR And CRISPR-Associated Genes Market Size 7 (2015-2020)8.4 China CRISPR And CRISPR-Associated Genes Market Size 4 (2015-2020) 9 Japan9.1 Japan CRISPR And CRISPR-Associated Genes Market Size (2015-2020)9.2 CRISPR And CRISPR-Associated Genes Key Players in Japan (2019-2020)9.3 Japan CRISPR And CRISPR-Associated Genes Market Size 7 (2015-2020)9.4 Japan CRISPR And CRISPR-Associated Genes Market Size 4 (2015-2020) 10 Southeast Asia10.1 Southeast Asia CRISPR And CRISPR-Associated Genes Market Size (2015-2020)10.2 CRISPR And CRISPR-Associated Genes Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia CRISPR And CRISPR-Associated Genes Market Size by Type (2015-2020)10.4 Southeast Asia CRISPR And CRISPR-Associated Genes Market Size by Application (2015-2020) 11 India11.1 India CRISPR And CRISPR-Associated Genes Market Size (2015-2020)11.2 CRISPR And CRISPR-Associated Genes Key Players in India (2019-2020)11.3 India CRISPR And CRISPR-Associated Genes Market Size by Type (2015-2020)11.4 India CRISPR And CRISPR-Associated Genes Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America CRISPR And CRISPR-Associated Genes Market Size (2015-2020)12.2 CRISPR And CRISPR-Associated Genes Key Players in Central & South America (2019-2020)12.3 Central & South America CRISPR And CRISPR-Associated Genes Market Size by Type (2015-2020)12.4 Central & South America CRISPR And CRISPR-Associated Genes Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Thermo Fisher Scientific13.1.1 Thermo Fisher Scientific Company Details13.1.2 Thermo Fisher Scientific Business Overview13.1.3 Thermo Fisher Scientific CRISPR And CRISPR-Associated Genes Introduction13.1.4 Thermo Fisher Scientific Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020))13.1.5 Thermo Fisher Scientific Recent Development13.2 Editas Medicine13.2.1 Editas Medicine Company Details13.2.2 Editas Medicine Business Overview13.2.3 Editas Medicine CRISPR And CRISPR-Associated Genes Introduction13.2.4 Editas Medicine Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.2.5 Editas Medicine Recent Development13.3 Caribou Biosciences13.3.1 Caribou Biosciences Company Details13.3.2 Caribou Biosciences Business Overview13.3.3 Caribou Biosciences CRISPR And CRISPR-Associated Genes Introduction13.3.4 Caribou Biosciences Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.3.5 Caribou Biosciences Recent Development13.4 CRISPR therapeutics13.4.1 CRISPR therapeutics Company Details13.4.2 CRISPR therapeutics Business Overview13.4.3 CRISPR therapeutics CRISPR And CRISPR-Associated Genes Introduction13.4.4 CRISPR therapeutics Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.4.5 CRISPR therapeutics Recent Development13.5 Intellia therapeutics, Inc.13.5.1 Intellia therapeutics, Inc. Company Details13.5.2 Intellia therapeutics, Inc. Business Overview13.5.3 Intellia therapeutics, Inc. CRISPR And CRISPR-Associated Genes Introduction13.5.4 Intellia therapeutics, Inc. Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.5.5 Intellia therapeutics, Inc. Recent Development13.6 Cellectis13.6.1 Cellectis Company Details13.6.2 Cellectis Business Overview13.6.3 Cellectis CRISPR And CRISPR-Associated Genes Introduction13.6.4 Cellectis Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.6.5 Cellectis Recent Development13.7 Horizon Discovery Plc13.7.1 Horizon Discovery Plc Company Details13.7.2 Horizon Discovery Plc Business Overview13.7.3 Horizon Discovery Plc CRISPR And CRISPR-Associated Genes Introduction13.7.4 Horizon Discovery Plc Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.7.5 Horizon Discovery Plc Recent Development13.8 Sigma Aldrich13.8.1 Sigma Aldrich Company Details13.8.2 Sigma Aldrich Business Overview13.8.3 Sigma Aldrich CRISPR And CRISPR-Associated Genes Introduction13.8.4 Sigma Aldrich Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.8.5 Sigma Aldrich Recent Development13.9 Precision Biosciences13.9.1 Precision Biosciences Company Details13.9.2 Precision Biosciences Business Overview13.9.3 Precision Biosciences CRISPR And CRISPR-Associated Genes Introduction13.9.4 Precision Biosciences Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.9.5 Precision Biosciences Recent Development13.10 Genscript13.10.1 Genscript Company Details13.10.2 Genscript Business Overview13.10.3 Genscript CRISPR And CRISPR-Associated Genes Introduction13.10.4 Genscript Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)13.10.5 Genscript Recent Development13.11 Sangamo Biosciences Inc.10.11.1 Sangamo Biosciences Inc. Company Details10.11.2 Sangamo Biosciences Inc. Business Overview10.11.3 Sangamo Biosciences Inc. CRISPR And CRISPR-Associated Genes Introduction10.11.4 Sangamo Biosciences Inc. Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)10.11.5 Sangamo Biosciences Inc. Recent Development13.12 Lonza Group Limited10.12.1 Lonza Group Limited Company Details10.12.2 Lonza Group Limited Business Overview10.12.3 Lonza Group Limited CRISPR And CRISPR-Associated Genes Introduction10.12.4 Lonza Group Limited Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)10.12.5 Lonza Group Limited Recent Development13.13 Integrated DNA Technologies10.13.1 Integrated DNA Technologies Company Details10.13.2 Integrated DNA Technologies Business Overview10.13.3 Integrated DNA Technologies CRISPR And CRISPR-Associated Genes Introduction10.13.4 Integrated DNA Technologies Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)10.13.5 Integrated DNA Technologies Recent Development13.14 New England Biolabs10.14.1 New England Biolabs Company Details10.14.2 New England Biolabs Business Overview10.14.3 New England Biolabs CRISPR And CRISPR-Associated Genes Introduction10.14.4 New England Biolabs Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)10.14.5 New England Biolabs Recent Development13.15 Origene Technologies10.15.1 Origene Technologies Company Details10.15.2 Origene Technologies Business Overview10.15.3 Origene Technologies CRISPR And CRISPR-Associated Genes Introduction10.15.4 Origene Technologies Revenue in CRISPR And CRISPR-Associated Genes Business (2015-2020)10.15.5 Origene Technologies Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details
About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
- 001 F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 15th, 2010] [Originally Added On: April 15th, 2010]
- 002 F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 16th, 2010] [Originally Added On: April 16th, 2010]
- 003 GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- 004 GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- 005 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 006 GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 007 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 008 GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 009 Stem Cell Therapy: Age of Human Cell Engineering is Born [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 010 Using Stem Cells Scientists Grow a Rat Lung, Humans are Next [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 011 How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 012 How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 013 Life Sciences at Oracle Open World 2010 [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 014 ChIP Enrichment Analysis can speed up drug discovery [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 015 GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 016 The SaaS impact on solution selling for ISVs (via Inner Lining) [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 017 Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 018 Life Sciences at Oracle Open World 2010 [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 019 ChIP Enrichment Analysis can speed up drug discovery [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 020 GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 021 The SaaS impact on solution selling for ISVs (via Inner Lining) [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 022 Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 023 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012 [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 024 Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 025 India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 026 Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 027 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012 [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 028 Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 029 India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 030 Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 031 Harvard Medical Schools new automated safety surveillance system provides faster early warnings in the postmarket evaluation of medical device safety [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 032 SalesForce.com partner introduces CRM for clinical trial management on Force Platform [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 033 Widespread fraud in the Clinical Trial of Drugs is pervasive event in United States [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 034 Scott Stern Kellogg School of Management speaks about “New Drug Development: From Laboratory to Blockbuster to Generic,” [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 035 collaborative clinical trials management software for Central Laboratories [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 036 MNC Pharma tries to capture the $1.9 billion Indian OTC market by selling Drugs through India’s 170000 post offices [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 037 Clinical Trial and Pharmacovigilance process automation [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 038 Microsoft in Clinical Trials Management System (CTMS) and Electronic Data Capture (EDC) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 039 Oracle Business Intelligence Enteprise Edition (OBIEE) for Clinical Trial Management System (CTMS) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 040 trends in the life sciences and pharma research and development outsourcing (RDO) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 041 Sanofi-Aventis ties up with Oxford Univ for oncology research in India [Last Updated On: December 17th, 2010] [Originally Added On: December 17th, 2010]
- 042 PharmaNet unveils touch screen capable data capture platform for Phase I Clinical Trials [Last Updated On: December 17th, 2010] [Originally Added On: December 17th, 2010]
- 043 Adverse Events in Hospitals- United States Department of Health Report slams current measures in US hospitals [Last Updated On: December 23rd, 2010] [Originally Added On: December 23rd, 2010]
- 044 IBM Files Application to Patent The Patent [Last Updated On: January 9th, 2011] [Originally Added On: January 9th, 2011]
- 045 How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 7th, 2011] [Originally Added On: February 7th, 2011]
- 046 Clinical Trial and Pharmacovigilance process automation [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 047 Microsoft in Clinical Trials Management System (CTMS) and Electronic Data Capture (EDC) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 048 Oracle Business Intelligence Enteprise Edition (OBIEE) for Clinical Trial Management System (CTMS) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 049 trends in the life sciences and pharma research and development outsourcing (RDO) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 050 Sanofi-Aventis ties up with Oxford Univ for oncology research in India [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 051 PharmaNet unveils touch screen capable data capture platform for Phase I Clinical Trials [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 052 Adverse Events in Hospitals- United States Department of Health Report slams current measures in US hospitals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 053 IBM Files Application to Patent The Patent [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 054 How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 055 AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 056 AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 057 Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 058 Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 059 Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 060 Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 061 Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 062 Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 063 Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 064 Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 065 Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 066 Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 067 Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- 068 Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- 069 Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- 070 Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- 071 One Way to Teach Your Boss About Social Media [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 072 “The Banks Can Do It, Why Can’t Hospitals?” [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 073 Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 074 Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 075 Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 076 Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 077 bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 078 SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- 079 privacy controlled social networking to connect patients with caregivers [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- 080 SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]